Brief: Tenaya Therapeutics Doses First Patient In Ridge-1 Phase 1B Clinical Trial Of TN-401
25/11/2024 13:47
Nov 25 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS DOSES FIRST PATIENT IN RIDGE™-1 PHASE
1B
CLINICAL TRIAL OF TN-401 FOR THE TREATMENT OF PKP2-ASSOCIATED
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
* TENAYA THERAPEUTICS INC - INITIAL CLINICAL DATA FOR
RIDGE-1
EXPECTED IN 2025
Source text: ID:nGNX6WM6b2
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027